Fate Therapeutics Financials - Benzinga

Fate Therapeutics Inc

FATENASDAQ

Trade with Public

Trade with Public

$2.45

0.020.82%

At close: Sep 1, 5:00 PM EST

$2.44

0.010.41%

Pre-Market: 6:07 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Fate Therapeutics Financials

Fate Therapeutics (FATE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from

Benzinga Newsdesk

PRO
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from

Benzinga Newsdesk

Fate Therapeutics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

Earnings Summary: Fate Therapeutics Q4

Benzinga Insights

PRO
Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 38.64 percent increase over losses of $(0.44) per share

Benzinga Newsdesk

PRO
Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from

Benzinga Newsdesk